NUWEHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2024 | Roth MKM | Reiterates | Buy | $17 |
| 29 July 2024 | Roth MKM | Initiates | Buy | — |
| 8 Nov 2023 | Ladenburg Thalmann | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUWE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 85% of US stocks
Cheaper than 92% of US stocks
Cheaper than 61% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 83% of US stocks
Higher than 12% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nuwellis, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the prepared remarks transcript from the event.
Why it matters — Earnings call transcripts provide direct insight into the company's operational performance and management's commentary, which can influence investor perception of Nuwellis.
Nuwellis, Inc. reported its financial results for the three and six months ended June 30, 2026, highlighting double-digit revenue growth and an expanded gross margin. The company also noted that a recent capital raise and warrant exercises extend its cash runway through the second quarter of 2027, with a conference call scheduled for 9:00 a.m. Eastern time.
Why it matters — A Nuwellis watcher would care because the results confirm double-digit revenue growth and improved gross margin, while the extended cash runway through Q2 2027 provides financial visibility for the company's cardiorenal-focused operations.
Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a record of advancing products from concept through commercial launch.
Why it matters — The appointment strengthens Nuwellis' product development organization with an experienced R&D leader who has a track record of moving medical devices from concept to market.
Nuwellis announced a next-generation strategy for its Aquadex platform, focusing on expanding the system's capabilities for immunomodulation, extracorporeal blood purification, and advanced critical care therapies.
Why it matters — This signals Nuwellis's intent to broaden the clinical applications of its core Aquadex platform beyond current uses, potentially opening larger market opportunities in critical care.
Nuwellis announced the pricing of a $3.4 million registered direct offering conducted at-the-market under Nasdaq rules, and separately received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.
Why it matters — A NUWE watcher would care because the new offering and warrant exercises indicate changes in the company's capital structure and near-term cash position.
Of the 1 analysts covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Nuwellis, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.
Nuwellis, Inc. returned -99.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Nuwellis Inc. is a medical technology company that develops, manufactures, and commercializes medical devices for ultrafiltration therapy to manage fluid overload in patients with cardiorenal conditions.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript". Nuwellis, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the prepared remarks transcript from the event.
Nuwellis Inc. is a medical technology company that develops, manufactures, and commercializes medical devices for ultrafiltration therapy to manage fluid overload in patients with cardiorenal conditions. Its primary products include the Aquadex FlexFlow and Aquadex SmartFlow systems, which provide clinicians with precise, safe methods to remove excess salt and water from patients whose conditions are unresponsive to diuretics, particularly those suffering from heart failure, critical care challenges, and pediatric cases. The Aquadex systems consist of a console with electromechanical pumps and display screen, disposable blood circuit sets with tubing, filters, sensors, and connectors, and disposable catheters. These devices support both temporary and extended use in adult and pediatric patients weighing 20 kilograms or more. Nuwellis Inc. markets its products to hospitals and clinics through a direct salesforce in the United States and independent specialty distributors in select international markets. The company also advances pediatric innovations like the Vivian pediatric system, focusing on safer fluid management in complex clinical scenarios. Founded in 1999 and headquartered in Eden Prairie, Minnesota, Nuwellis Inc. plays a key role in enhancing cardiorenal care by centralizing fluid management in treatment protocols.
CEO Mr. John L. Erb · 38 employees · United States · https://www.nuwellis.com